WASHINGTON, Nov. 11 -- Eli Lilly, Indianapolis, Indiana, has submitted a public comment letter to the Office of Science and Technology Policy addressing regulatory challenges impacting the integration of artificial intelligence (AI) in drug development and clinical trials. Lilly emphasized the need for a more streamlined regulatory framework that accommodates the unique nature of AI technology while safeguarding public health. In its letter, Lilly articulated that current regulatory structures,  more